Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03088540 · OUTCOME

Progression-free Survival (PFS) Per Blinded IRC

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) · Source last updated 2026-06-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 94 months

What was measured

PFS as assessed by blinded IRC per RECIST 1.1 was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.

Analysis population: FAS included all randomized participants.

Groups in this outcome

Cemiplimab

Participants received cemiplimab monotherapy

Chemotherapy

Participants received platinum-based doublet chemotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cemiplimab357
Chemotherapy355

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Cemiplimab6.3Not reported4.68.3Not reported
Chemotherapy5.3Not reported4.36.0Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.469
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    0.665
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    <0.0001
    p Value Comment
    All analyses based on final DBL were descriptive only with p-values reported as nominal.
    param Type
    Hazard Ratio (HR)
    param Value
    0.559
    statistical Method
    Stratified log-rank
Complete source fields
analyses
  1. ci Lower Limit
    0.469
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    0.665
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    <0.0001
    p Value Comment
    All analyses based on final DBL were descriptive only with p-values reported as nominal.
    param Type
    Hazard Ratio (HR)
    param Value
    0.559
    statistical Method
    Stratified log-rank
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4.6
        upper Limit
        8.3
        value
        6.3
      2. group Id
        OG001
        lower Limit
        4.3
        upper Limit
        6.0
        value
        5.3
denoms
  1. counts
    1. group Id
      OG000
      value
      357
    2. group Id
      OG001
      value
      355
    units
    Participants
description
PFS as assessed by blinded IRC per RECIST 1.1 was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants received cemiplimab monotherapy
    id
    OG000
    title
    Cemiplimab
  2. description
    Participants received platinum-based doublet chemotherapy
    id
    OG001
    title
    Chemotherapy
param Type
MEDIAN
population Description
FAS included all randomized participants.
reporting Status
POSTED
time Frame
Up to 94 months
title
Progression-free Survival (PFS) Per Blinded IRC
type
PRIMARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice